The mechanisms of thrombotic risk induced by hormone replacement therapy.
OBJECTIVE
To review the available information on the action of hormones on the mechanisms involved in thrombotic risk.


CONCLUSIONS
Thrombosis plays a crucial role in the genesis and progression of both coronary heart disease (CHD) and venous thromboembolic disease (VTED), the two main forms of cardiovascular disease. Two main determinants of the thromboembolic phenotype, hypercoagulable state and altered endothelium, accumulate much of the work performed on the influence of hormones on thrombosis. Information has accumulated mainly for oestrogens, but increasing evidences support a role for progestogens. The sensitivity of each of the three components of the hemostatic balance, the coagulation cascade, the anticoagulant system and fibrinolysis, to oestrogens has been widely examined in the literature. Functional tests suggest that HRT is accompanied by a procoagulant state. Much of the work has concentrated on changes induced on reputable indicators of risk for either CHD or VTED. Distinct indicators of increased coagulability, such as resistance to activated C protein, antithrombin or tissue factor pathway inhibitor have been selected for VTED, whereas factor VII, fibrinogen, and defective fibrinolysis, for CHD. Different states of genetic susceptibility have been involved in both forms of the disease. The status of health of endothelium, defines another scenario for attention in CHD. A long-term anti-atherogenic action of oestrogens, which may be associated with short-term risk in cases of atherosclerosis-induced endothelial dysfunction, may most adequately explain much of the clinical observation. In both CHD and VTED, the procoagulant changes initiate soon after HRT administration.
Cano
A
A
Department of Pediatrics, Obstetrics and Gynecology, Faculty of Medicine and Dentistry, University of Valencia, Avda. Blasco Ibañez, 17, E 46010 Valencia, Spain. antonio.cano@uv.es
Van Baal
W M
WM
D000368:Aged; D001161:Arteriosclerosis / Q000503:physiopathology; D001792:Blood Platelets; D003327:Coronary Disease / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control*; D004730:Endothelium, Vascular / Q000503:physiopathology; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D006487:Hemostasis / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D017698:Postmenopause / Q000187:drug effects; D012307:Risk Factors; D020246:Venous Thrombosis / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology / Q000235:genetics
D004967:Estrogens